Analysis of Potential Transcriptomic Biomarkers for Huntington's Disease in Peripheral Blood

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2007 Aug 29

PMID 17724341

Citations 66

Authors

Heike Runne

Alexandre Kuhn

Edward J Wild

Wirahpati Pratyaksha

Mark Kristiansen

Jeremy D Isaacs

Etienne Regulier

Mauro Delorenzi

Sarah J Tabrizi

Ruth Luthi-Carter

Affiliations

Soon will be listed here.

Abstract

Highly quantitative biomarkers of neurodegenerative disease remain an important need in the urgent quest for disease-modifying therapies. For Huntington's disease (HD), a genetic test is available (trait marker), but necessary state markers are still in development. In this report, we describe a large battery of transcriptomic tests explored as state biomarker candidates. In an attempt to exploit the known neuroinflammatory and transcriptional perturbations of disease, we measured relevant mRNAs in peripheral blood cells. The performance of these potential markers was weak overall, with only one mRNA, immediate early response 3 (IER3), showing a modest but significant increase of 32% in HD samples compared with controls. No statistically significant differences were found for any other mRNAs tested, including a panel of 12 RNA biomarkers identified in a previous report [Borovecki F, Lovrecic L, Zhou J, Jeong H, Then F, Rosas HD, Hersch SM, Hogarth P, Bouzou B, Jensen RV, et al. (2005) Proc Natl Acad Sci USA 102:11023-11028]. The present results may nonetheless inform the future design and testing of HD biomarker strategies.

Citing Articles

Inflammasomes in neurodegenerative diseases.

Wang Q, Yang S, Zhang X, Zhang S, Chen L, Wang W Transl Neurodegener. 2024; 13(1):65.

PMID: 39710713 PMC: 11665095. DOI: 10.1186/s40035-024-00459-0.

Exploring Intrinsic Disorder in Human Synucleins and Associated Proteins.

Venati S, Uversky V Int J Mol Sci. 2024; 25(15).

PMID: 39125972 PMC: 11313516. DOI: 10.3390/ijms25158399.

Ant colony optimization for the identification of dysregulated gene subnetworks from expression data.

Hanna E, El Hasbani G, Azar D BMC Bioinformatics. 2024; 25(1):254.

PMID: 39090538 PMC: 11295523. DOI: 10.1186/s12859-024-05871-x.

A standardised protocol for blood and cerebrospinal fluid collection and processing for biomarker research in ataxia.

Santana M, Gaspar L, Pinto M, Silva P, Adao D, Pereira D Neuropathol Appl Neurobiol. 2023; 49(2):e12892.

PMID: 36798010 PMC: 10947376. DOI: 10.1111/nan.12892.

At-home blood collection and stabilization in high temperature climates using RNA.

Brown L, Haack A, Kennedy D, Adams K, Stolarczuk J, Takezawa M Front Digit Health. 2022; 4:903153.

PMID: 36033636 PMC: 9405416. DOI: 10.3389/fdgth.2022.903153.

References

Henley S, Bates G, Tabrizi S . Biomarkers for neurodegenerative diseases. Curr Opin Neurol. 2005; 18(6):698-705. DOI: 10.1097/01.wco.0000186842.51129.cb. View

Leblhuber F, Walli J, Jellinger K, Tilz G, Widner B, Laccone F . Activated immune system in patients with Huntington's disease. Clin Chem Lab Med. 1998; 36(10):747-50. DOI: 10.1515/CCLM.1998.132. View

Shoulson I, Fahn S . Huntington disease: clinical care and evaluation. Neurology. 1979; 29(1):1-3. DOI: 10.1212/wnl.29.1.1. View

Singhrao S, Neal J, Morgan B, Gasque P . Increased complement biosynthesis by microglia and complement activation on neurons in Huntington's disease. Exp Neurol. 1999; 159(2):362-76. DOI: 10.1006/exnr.1999.7170. View

Bolstad B, Irizarry R, Astrand M, Speed T . A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics. 2003; 19(2):185-93. DOI: 10.1093/bioinformatics/19.2.185. View

Luthi-Carter R, Hanson S, Strand A, Bergstrom D, Chun W, Peters N . Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. Hum Mol Genet. 2002; 11(17):1911-26. DOI: 10.1093/hmg/11.17.1911. View

Borovecki F, Lovrecic L, Zhou J, Jeong H, Then F, Rosas H . Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease. Proc Natl Acad Sci U S A. 2005; 102(31):11023-8. PMC: 1182457. DOI: 10.1073/pnas.0504921102. View

Butler R, Bates G . Histone deacetylase inhibitors as therapeutics for polyglutamine disorders. Nat Rev Neurosci. 2006; 7(10):784-96. DOI: 10.1038/nrn1989. View

Gautier L, Cope L, Bolstad B, Irizarry R . affy--analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 2004; 20(3):307-15. DOI: 10.1093/bioinformatics/btg405. View

10.

Heuser I, Chase T, Mouradian M . The limbic-hypothalamic-pituitary-adrenal axis in Huntington's disease. Biol Psychiatry. 1991; 30(9):943-52. DOI: 10.1016/0006-3223(91)90007-9. View

11.

Smyth G . Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2006; 3:Article3. DOI: 10.2202/1544-6115.1027. View

12.

Paulsen J, Hayden M, Stout J, Langbehn D, Aylward E, Ross C . Preparing for preventive clinical trials: the Predict-HD study. Arch Neurol. 2006; 63(6):883-90. DOI: 10.1001/archneur.63.6.883. View

13.

Hodges A, Strand A, Aragaki A, Kuhn A, Sengstag T, Hughes G . Regional and cellular gene expression changes in human Huntington's disease brain. Hum Mol Genet. 2006; 15(6):965-77. DOI: 10.1093/hmg/ddl013. View

14.

Boyum A . Isolation of leucocytes from human blood. A two-phase system for removal of red cells with methylcellulose as erythrocyte-aggregating agent. Scand J Clin Lab Invest Suppl. 1968; 97:9-29. View

15.

Hunot S, Hirsch E . Neuroinflammatory processes in Parkinson's disease. Ann Neurol. 2003; 53 Suppl 3:S49-58; discussion S58-60. DOI: 10.1002/ana.10481. View

16.

Whitney A, Diehn M, Popper S, Alizadeh A, Boldrick J, Relman D . Individuality and variation in gene expression patterns in human blood. Proc Natl Acad Sci U S A. 2003; 100(4):1896-901. PMC: 149930. DOI: 10.1073/pnas.252784499. View

17.

Bonifati D, Kishore U . Role of complement in neurodegeneration and neuroinflammation. Mol Immunol. 2006; 44(5):999-1010. DOI: 10.1016/j.molimm.2006.03.007. View

18.

Wild E, Tabrizi S . Predict-HD and the future of therapeutic trials. Lancet Neurol. 2006; 5(9):724-5. DOI: 10.1016/S1474-4422(06)70531-2. View

19.

Petersen A, Bjorkqvist M . Hypothalamic-endocrine aspects in Huntington's disease. Eur J Neurosci. 2006; 24(4):961-7. DOI: 10.1111/j.1460-9568.2006.04985.x. View

20.

Strand A, Aragaki A, Shaw D, Bird T, Holton J, Turner C . Gene expression in Huntington's disease skeletal muscle: a potential biomarker. Hum Mol Genet. 2005; 14(13):1863-76. DOI: 10.1093/hmg/ddi192. View